Kastle Therapeutics, which is backed by Flexpoint Ford, has named Michael Shih as vice president of business development and chief legal counsel. Previously, Shih worked at Epizyme Inc where he served as vice president of business development. Based in Chicago, Kastle is a biopharmaceutical company focused on developing drugs for diseases with “high unmet medical needs.”
CHICAGO, Sept. 16, 2015 /PRNewswire/ — Kastle Therapeutics (Kastle), a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceuticals, announced today that it has appointed Michael Shih to the role of Vice President, Business Development and Chief Legal Counsel.
Michael has held a number of executive business development roles in the biopharmaceutical industry. Most recently, he served as Vice President of Business Development at Epizyme, Inc., a clinical-stage biotechnology company. Prior to his tenure at Epizyme, Michael was Senior Director of Business Development at Forest Laboratories, where he focused on in-licensing and acquiring commercial and clinical therapeutics across a wide range of therapeutic areas. Michael has also held positions at Eisai, both in business development and as in-house legal counsel where he supported a wide variety of business functions, such as mergers & acquisitions, business development and corporate transactions and litigation. Michael is an attorney by training and began his career in several New York law firms as an intellectual property and transactional attorney focused on the life sciences.
“Michael’s experience in screening, sourcing and negotiating strategic transactions makes him a highly valuable addition to the Kastle team,” said Bryan Stuart, Kastle’s President. “In addition, his diverse corporate experience across a wide variety of therapeutic areas, as well as his extensive legal background, will benefit Kastle as we grow the company.”
Michael’s appointment is effective immediately.
About Kastle Therapeutics
Kastle Therapeutics (Kastle) is a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceuticals for diseases with high unmet medical needs. Kastle is backed by Flexpoint Ford and has an initial acquisition capacity in excess of $250 million. The company is headquartered in Chicago. For more information, please visit www.kastletherapeutics.com.
About Flexpoint Ford
With offices in Chicago and New York, Flexpoint Ford is a private equity investment firm with over $2 billion under management, specializing in privately negotiated investments in the healthcare and financial services industries. For more information, please visit www.flexpointford.com.